Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 14 Sept 2022 |
| Orion Corporation: Acquisition of Own Shares 13.09.2022 | 13 Sept 2022 |
| Orion Corporation: Acquisition of Own Shares 12.09.2022 | 12 Sept 2022 |
| Orion Corporation: Acquisition of Own Shares 09.09.2022 | 9 Sept 2022 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 08.09.2022 | 8 Sept 2022 |